Enzo Biochem, Inc.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US2941001024

USD

0.70

0.01 (1.66%)

Aug 19

NYS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

NanoString Technologies, Inc.

Enzo Biochem, Inc.

Eliem Therapeutics, Inc.

BioAtla, Inc.

BioXcel Therapeutics, Inc.

Jasper Therapeutics, Inc.

YS Biopharma Co. Ltd.

Athira Pharma, Inc.

Turnstone Biologics Corp.

Vaccinex, Inc.

Affimed NV

Why is Enzo Biochem, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

No Data Found

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-19.28%

EBIT Growth (5y)

9.74%

EBIT to Interest (avg)

-12.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.82

Sales to Capital Employed (avg)

1.06

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

36.14%

ROCE (avg)

0.33%

ROE (avg)

1.91%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.67

EV to EBIT

0.94

EV to EBITDA

1.12

EV to Capital Employed

-1.06

EV to Sales

-0.27

PEG Ratio

Dividend Yield

1581.60%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-12.03%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at USD -2.81 MM

-14What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -1.91 MM has Fallen at -36.14%

NET PROFIT(Q)

At USD -1.91 MM has Fallen at -36.14%

RAW MATERIAL COST(Y)

Grown by 16.98% (YoY

NET SALES(Q)

At USD 6.4 MM has Fallen at -11.98%

Here's what is not working for Enzo Biochem, Inc.

Pre-Tax Profit

At USD -1.91 MM has Fallen at -36.14%

over average net sales of the previous four periods of USD -1.4 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -1.91 MM has Fallen at -36.14%

over average net sales of the previous four periods of USD -1.4 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

At USD 6.4 MM has Fallen at -11.98%

over average net sales of the previous four periods of USD 7.27 MM

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Raw Material Cost

Grown by 16.98% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales